A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Docetaxel (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 21 Aug 2017 Status changed from not yet recruiting to recruiting.